These long-acting incretin receptor agonists have revolutionized the landscape of obesity and T2D research and are now being explored for other metabolic disorders, including non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) [3]
When to seek medical advice : Patients should contact their GP, diabetes specialist nurse, or NHS 111 urgently if they experience: Severe, persistent abdominal pain, especially if radiating to the back (possible pancreatitis) Persistent vomiting (unable to keep down fluids for more than 24 hours) Signs of dehydration (extreme thirst, dry mouth, reduced urination, dizziness) Fever, jaundice, or right upper abdominal pain (possible gallbladder disease) If nausea significantly impacts their ability to maintain adequate nutrition These symptoms may warrant dose reduction, temporary treatment interruption, or switching to an alternative GLP-1 preparation with a potentially better tolerability profile
Purpose: Therapeutic dose range
Rotation of injection sites is strongly recommended
Talk to your provider if this is happening repeatedly
NCT04093752) and insulin lispro (ClinicalTrials.gov registration no